Soleno Therapeutics Inc (SLNO) gains 4.64% for July 21

Equities Staff  |

Soleno Therapeutics Inc (NASDAQ: SLNO) shares gained 4.64%, or $0.0439 per share, to close Wednesday at $0.99. After opening the day at $0.96, shares of Soleno fluctuated between $1.01 and $0.96. 393,580 shares traded hands a decrease from their 30 day average of 1,192,821. Wednesday's activity brought Soleno’s market cap to $78,977,585.

Soleno is headquartered in Redwood City, California..

About Soleno Therapeutics Inc

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program.

Visit Soleno Therapeutics Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Soleno Therapeutics Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Soleno Therapeutics Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content